CD8A and neoplasm: For example, targeting FGFR using lentivatinib aids to improve anti-PD-1 efficiency via reducing tumor PD-L1 level and Treg differentiation [235], remodeling immunosuppressive TME and increasing functional CD8+ T cells [236].